Literature DB >> 25544880

Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI.

Shunsuke Nojiri1, Kei Fujiwara1, Noboru Shinkai1, Mio Endo1, Takashi Joh1.   

Abstract

AIM: To evaluate the efficacy of ethoxibenzyl-magnetic resonance imaging (EOB-MRI) as a predictor of hepatocellular carcinoma (HCC) development.
METHODS: Between August 2008 and 2009, we studied 142 hepatitis C virus-infected patients (male 70, female 72), excluding those with HCC or a past history, who underwent EOB-MRI in our hospital. The EOB-MRI index [liver-intervertebral disc ratio (LI)] was calculated as: (post-liver intensity/post-intervertebral disc intensity)/(pre-liver intensity/pre-intervertebral disc intensity).
RESULTS: The median follow-up period was 3.1 years and the patients were observed until the end of the study period (31 December, 2012). In the follow-up period, HCC occurred in 21 patients. The cumulative occurrence rates were 2.1%, 9.1%, and 14.1% at 1, 2, and 3 years, respectively. Using the optimal cut-off value of LI 1.46, on univariate analysis, age, aspartate amino transferase (AST), α-fetoprotein (AFP) ≥ 10, albumin, total cholesterol, prothrombin time, platelets, and LI < 1.46 were identified as independent factors, but on multivariate analysis, LI < 1.46: risk ratio 6.05 (1.34-27.3, P = 0.019) and AFP ≥ 10: risk ratio 3.1 (1.03-9.35, P = 0.045) were identified as independent risk factors. LI and Fib-4 index have higher area under the receiver operating characteristic curves than other representative fibrosis evaluation methods, such as Forn's index and AST-to-platelet ratio index.
CONCLUSION: LI is associated with the risk of HCC occurrence in hepatitis C patients. LI may be a substitute for liver biopsy when evaluating this risk and its combined use with Fib-4 is a better predictive method of HCC progression.

Entities:  

Keywords:  Ethoxibenzyl-magnetic resonance imaging; Fibrosis; Hepatocellular carcinoma; Risk factor

Year:  2014        PMID: 25544880      PMCID: PMC4269912          DOI: 10.4254/wjh.v6.i12.930

Source DB:  PubMed          Journal:  World J Hepatol


  41 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

Authors:  Yen Ngo; Mona Munteanu; Djamila Messous; Frederic Charlotte; Françoise Imbert-Bismut; Dominique Thabut; Pascal Lebray; Vincent Thibault; Yves Benhamou; Joseph Moussalli; Vlad Ratziu; Thierry Poynard
Journal:  Clin Chem       Date:  2006-08-24       Impact factor: 8.327

3.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

4.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

5.  Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Satoshi Goshima; Hiroshi Kondo; Minoru Onozuka; Noriyuki Moriyama; Kyongtae T Bae
Journal:  Radiology       Date:  2011-01-19       Impact factor: 11.105

6.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

7.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA.

Authors:  Hun-Kyu Ryeom; Seong-Hun Kim; Jong-Yeol Kim; Hye-Jeong Kim; Jong-Min Lee; Yong-Min Chang; Yong-Sun Kim; Duk-Sik Kang
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

9.  Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time?

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Licht Tominaga; Hironobu Sou; Katsuhiro Sano; Shintaro Ichikawa; Tsutomu Araki
Journal:  Eur Radiol       Date:  2009-05-27       Impact factor: 5.315

10.  Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.

Authors:  Namiki Izumi; Yasuhiro Asahina; Masayuki Kurosaki; Gotaro Yamada; Tsutomu Kawai; Eiji Kajiwara; Yukishige Okamura; Takayuki Takeuchi; Osamu Yokosuka; Kazuya Kariyama; Joji Toyoda; Mie Inao; Eiji Tanaka; Hisataka Moriwaki; Hiroshi Adachi; Shinji Katsushima; Masatoshi Kudo; Kouichi Takaguchi; Yoichi Hiasa; Kazuaki Chayama; Hiroshi Yatsuhashi; Makoto Oketani; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-08-09       Impact factor: 7.527

View more
  2 in total

1.  Hyperintensity at fat spared area in steatotic liver on the hepatobiliary phase MRI.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Ali Devrim Karaosmanoğlu; Mustafa Nasuh Özmen; Deniz Akata; Muşturay Karcaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2019-11       Impact factor: 2.630

2.  Mitochondrial DNA Haplogroup N9a Negatively Correlates with Incidence of Hepatocellular Carcinoma in Northern China.

Authors:  Shixuan Hua; Meinan Li; Qiongya Zhao; Junyi Wang; Yaping Zhou; Jiangtao Liu; Hezhi Fang; Minghua Jiang; Lijun Shen
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-12       Impact factor: 8.886

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.